Gemoxen 1 gm/vial (IV Infusion)

1 gm vial: ৳ 5,500.00

Medicine Details

Category Details
Generic Gemcitabine
Company Beacon pharmaceuticals plc
Also available as
Gemoxen 200 mg injection

Title

  • Gemoxen 1000mg Injection

Categories

  • Anti-Cancer Medication
  • Chemotherapy
  • Oncology

Description

  • Gemoxen 1000mg injection is indicated for the first-line treatment of non-small cell lung cancer, pancreatic cancer, bladder cancer, breast cancer, and ovarian cancer.
  • It is also used in combination with Cisplatin, Paclitaxel, and Carboplatin for different cancer treatments.

Dosage

  • The recommended dose for non-small cell lung cancer is 1000 mg/m2 given by a 30-minute intravenous infusion, with variations for single-agent use and combination use.
  • For pancreatic cancer, the recommended dose is 1000 mg/m2 given by a 30-minute intravenous infusion, repeated once weekly for up to 7 weeks followed by a week of rest.
  • For bladder cancer, the recommended dose varies for single-agent use and combination use.
  • For breast cancer, Gemoxen is recommended to be used in combination with Paclitaxel, with specific dosage instructions.
  • For ovarian cancer, Gemoxen is recommended to be used in combination with Carboplatin, with specific dosage instructions.

Pharmacology

  • Gemcitabine (dFdC) is metabolized intracellularly by nucleoside kinases to the active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides.
  • The cytotoxic action of Gemcitabine appears to be due to inhibition of DNA synthesis by dFdCDP and dFdCTP.
  • It also induces the programmed cellular death process known as apoptosis.

Interaction

  • No confirmed interactions have been reported with the use of Gemoxen.
  • No specific drug interaction studies have been conducted.

Contraindications

  • Gemoxen is contraindicated in patients with known hypersensitivity to Gemcitabine or any other components of this product.

Side Effects

  • Gemoxen may cause haematological toxicity including anaemia, leukopenia, and thrombocytopenia.
  • Hepatic toxicity and gastrointestinal effects such as nausea, vomiting, and diarrhoea are also reported.
  • Genito-urinary, pulmonary, allergic, and neurotoxicity effects are observed, along with alopecia.
  • Rare cases of renal failure and pulmonary oedema have been reported.

Pregnancy & Lactation

  • Gemcitabine is categorized as Pregnancy Category D and should be used with caution during pregnancy.
  • It is not known whether Gemcitabine is excreted in human breast milk.

Precautions & Warnings

  • Caution should be exercised when using Gemoxen in patients with the risk of schedule-dependent toxicity, myelosuppression, pulmonary toxicity, respiratory failure, hemolytic uremic syndrome, and hepatic toxicity.

Use in Special Populations

  • Elderly Patients: Gemoxen has been well tolerated in patients over the age of 65.
  • Renal and Hepatic Impairment: Gemoxen should be used with caution in patients with impaired renal function or hepatic insufficiency.
  • Children: Limited data available for pediatric use.

Overdose Effects

  • There is no known antidote for overdoses of Gemoxen.
  • In the event of suspected overdose, the patient should be monitored with appropriate blood counts and receive supportive therapy as necessary.

Therapeutic Class

  • Cytotoxic Chemotherapy

Storage Conditions

  • Store the vial in the original carton at 20°C to 25°C, away from light.
  • Do not refrigerate as crystallization may occur.
  • Keep out of the reach of children.

OtherAttributes

  • Metabolised intracellularly by nucleoside kinases
  • Indicated for locally advanced or metastatic cancers
  • Mode of Action involves inhibition of DNA synthesis
  • No specific drug interaction studies conducted
  • Potential contraindication for patients with known hypersensitivity to Gemcitabine or any other components
  • Various side effects including haematological, hepatic, gastrointestinal, genito-urinary, pulmonary, allergic, and neurotoxicity effects reported
  • Consideration for use in elderly, renal and hepatic impairment, and pediatric population
  • No known antidote for overdoses of Gemoxen
  • Storage conditions at 20-25°C away from light

Related Brands